STING1 and neoplasm: A recent trial (CTR20230372) demonstrated that combining the oral STING agonist MSA-2 with the anti-TGF-β/PD-L1 bispecific antibody YM101 could enhance anti-tumor immunity in immune-silent tumor models (e.g., immune-excluded and immune-desert) (76).